http://www.codesria.org/?q=1&p...he-counter http://www.codesria.org/?q=1&p...riligy-buy http://www.codesria.org/?q=1&p...eight-loss cephalexin pills expire venlafaxine hcl er 150 mg
acheter cialis 5mg france 
http://www.capitalvision.fr/ma...per-active 
viagra generico spedizione rapida 
acquista viagra online 
http://www.capitalvision.fr/ma...one-medica 
http://www.javafilms.fr/?comps...le-ricetta http://www.javafilms.fr/?comps...ei-holland ou commander du viagra sur internet http://www.javafilms.fr/?comps...ei-spanien cialis alle erbe achat cialis ligne venta cialis compra de viagra contrareembolso viagra en gotas para hombres donde se compra viagra
    effexor tablets dosage keflex 1000 mg bid http://he.manhigut.org/?itemid...s-bp-50-mg http://he.manhigut.org/?itemid...d-for-sale unprescribed clomid

Lymphoseek designated fast track status in head and neck cancer

Wed, Dec 11, 2013

Oral Cancer News

Source: www.empr.com
Author: press release

Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes.

Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.